Active substancePhospholipidsPhospholipids
Similar drugsTo uncover
  • Antralive®
    capsules inwards 
  • L'esfal
    solution in / in 
    FARMAK, PAO     Ukraine
  • Livenciale
    solution in / in 
    Rowecq Limited     United Kingdom
  • Livolife Forte
    capsules inwards 
    KORAL-MED, CJSC     Russia
  • Phosphontsiale®
    capsules inwards 
  • Phosphontsiale® Mono
    solution in / in 
    Bakter, OOO     Russia
  • Essentiale® H
    solution in / in 
  • Essentiale® Fort H
    capsules inwards 
  • Essential phospholipids
    capsules inwards 
    ATOLL, LLC     Russia
  • Essley forte
    capsules inwards 
    ATOLL, LLC     Russia
  • Essley®
    solution in / in 
  • Dosage form: & nbspsolution for intravenous administration
    Composition:

    For 5 ml:

    active substance: Soybean phospholipids in terms of phosphatidylcholine - 250.0 mg;

    Excipients: sodium hydroxide 0.1 M q.s. up to pH 7.5-9.5, gasoline - 45.0 mg, water for injection up to 5.0 ml.

    Description:

    Transparent solution from light yellow to yellow with a specific odor

    Pharmacotherapeutic group:Hepatoprotective agent
    ATX: & nbsp

    A.05.C   Combination of drugs for the treatment of diseases of the liver and biliary tract

    Pharmacodynamics:

    Hepatoprotective agent; included in phospholipids are the main elements in the structure of the cell membrane and mitochondria. Regulates lipid and carbohydrate metabolism, improves the functional state of the liver and its detoxification function, promotes the preservation and restoration of the structure of hepatocytes; inhibits the formation of connective tissue in the liver.

    Pharmacokinetics:

    Linking mainly with high-density lipoproteins, phosphatidylcholine enters, in particular, into liver cells. The half-life of the choline component is 66 hours, and the unsaturated fatty acid is 32 hours.

    Indications:

    Fatty degeneration of the liver (including diabetes mellitus); acute and chronic hepatitis, cirrhosis of the liver, necrosis of liver cells, hepatic coma and precoma, toxic liver damage; toxicosis of pregnancy; pre- and postoperative treatment, especially, in operations in the field of the hepatobiliary zone; psoriasis (as an auxiliary therapy); radiation syndrome.

    Contraindications:

    Hypersensitivity, children under 18 years of age, intolerance to soy.

    Carefully:Pregnancy.
    Pregnancy and lactation:

    In pregnancy, due to the presence of benzyl alcohol in the formulation, which can penetrate through the placental barrier (the use of drugs containing petrol alcohol, in neonatal or preterm infants born in time was associated with the development of shortness of breath in fatal cases), the drug can only be used in cases where the expected benefit of therapy for the mother exceeds the potential risk to the fetus.

    Do not recommend to use during breastfeeding due to the lack of data on the safety of the drug.

    Dosing and Administration:

    Intravenous (dropwise, at a speed of 40-50 cap / min, dissolving in 250-300 ml of 5% dextrose solution, or in / in struyno, pre-dilute the patient's blood in a 1: 1 ratio), 1-2 ampoules (5-10 ml ) per day or in severe cases 2-4 ampoules (10-20 ml) per day. As the patient's condition improves, parenteral administration is replaced as soon as possible by oral administration of the drug. The course of treatment - 3 months, if necessary, can be continued or repeated.

    Treatment of psoriasis begins with a 2-week capsule intake (600 mg 3 times a day), then 10 intravenous infusions of 250 mg daily are administered and simultaneously PUVA therapy begins. After completion of the infusion, the capsules are resumed for 2 months.In the presence of contraindications to PUVA-therapy are limited to the use of the drug according to the above procedure, incl. in combination with conventional methods of treatment of psoriasis.

    Do not dilute the drug with electrolyte solutions (0.9% solution of sodium chloride, Ringer's solution)!

    Side effects:

    From the digestive system: when used in high doses - diarrhea.

    From the immune system: reactions of hypersensitivity, incl. skin allergic reactions: skin rash, itchy skin, exanthema or urticaria.

    Overdose:

    No cases of overdose have been reported.

    Interaction:

    Pharmaceutically incompatible with solutions of electrolytes.

    Special instructions:

    Parenteral only enter clear solutions.

    Form release / dosage:

    Solution for intravenous administration of 250 mg / 5 ml.

    Packaging:

    For 5 ml of the drug in dark glass ampoules (type 1, F. USA).

    5 ampoules per plastic pallet.

    Each pallet together with instructions for use in a pack of cardboard.

    Storage conditions:

    In the dark place at a temperature of 2 to 8 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use the drug after the expiration date

    Terms of leave from pharmacies:On prescription
    Registration number:LP-002728
    Date of registration:26.11.2014 / 20.05.2016
    Expiration Date:26.11.2019
    The owner of the registration certificate:Rowecq LimitedRowecq Limited United Kingdom
    Manufacturer: & nbsp
    Representation: & nbspROUTEC LIMITEDROUTEC LIMITEDUnited Kingdom
    Information update date: & nbsp28.02.2018
    Illustrated instructions
      Instructions
      Up